DRIOHealthcare · Health Information ServicesThe 4 Wall Street analysts covering DarioHealth Corp. hold a median 12-month price target of $12 — +49.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 11 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores DarioHealth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (13): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DRIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +49.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 May 2026 | Stifel | Reiterates | Buy | $10 |
| 13 May 2026 | TD Cowen | Maintains | Hold | $11 |
| 20 Mar 2026 | Stifel | Maintains | Buy | — |
| 19 May 2025 | Litchfield Hills | Initiates | Buy | — |
| 11 Mar 2025 | Stifel | Maintains | Buy | — |
| 1 Apr 2024 | Stifel | Maintains | Buy | — |
| 11 Aug 2023 | Alliance Global Partners | Maintains | Buy | — |
| 25 July 2023 | Stifel | Maintains | Buy | — |
| 12 May 2023 | Craig-Hallum | Maintains | Buy | — |
| 16 Nov 2022 | Alliance Global Partners | Maintains | Buy | — |
| 18 Aug 2022 | Aegis Capital | Maintains | Buy | — |
| 16 Aug 2022 | Cowen & Co. | Maintains | Outperform | — |
| 16 May 2022 | Aegis Capital | Maintains | Buy | — |
| 16 May 2022 | Cowen & Co. | Maintains | Outperform | — |
| 13 May 2022 | Alliance Global Partners | Upgrade | Buy | — |
| 26 Jan 2022 | Aegis Capital | Maintains | Buy | — |
| 19 Aug 2021 | Aegis Capital | Maintains | Buy | — |
| 22 Apr 2021 | Cowen & Co. | Initiates | Outperform | — |
| 23 Mar 2021 | Stifel | Initiates | Buy | — |
| 8 Feb 2021 | Aegis Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRIO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 36% of US stocks
Cheaper than 76% of US stocks
Cheaper than 72% of US stocks
Higher than 12% of US stocks
Higher than 21% of US stocks
Higher than 71% of US stocks
Higher than 12% of US stocks
Higher than 2% of US stocks
Higher than 19% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DarioHealth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
DarioHealth Corp. held its Q2 2026 earnings call, and Seeking Alpha published the corresponding transcript of the event. The call covers the company's second-quarter 2026 financial results and commentary.
Why it matters — DRIO watchers would review this transcript for management's discussion of the company's Q2 2026 performance and outlook.
DarioHealth reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the prior quarter and $5.4 million a year earlier. The decline reflects the company's continued shift away from pharmaceutical services revenue toward recurring B2B2C business.
Why it matters — DRIO watchers would track the quarterly revenue decline and the company's ongoing transition to recurring B2B2C revenue as it reshapes its business mix.
DarioHealth Corp. reported a second-quarter loss of $0.57 per share, narrower than the Zacks Consensus Estimate of a $0.76 loss and an improvement from the $2.40 per share loss a year earlier.
Why it matters — A DRIO watcher would care because the company beat consensus loss estimates and narrowed its year-over-year loss, indicating improving quarterly financial performance.
DarioHealth reported second-quarter 2026 revenue of $5.2 million, with gross margin rising to 62% and operating loss down 30% year-over-year. The company highlighted commercial momentum including a top-5 national health plan expansion, and completed an at-the-market financing raising $22.8 million in net proceeds.
Why it matters — The results show improving margins and cost discipline alongside multi-condition revenue growth and expanded commercial distribution, which are key drivers for DarioHealth investors to track.
DarioHealth announced the launch of Dario Women and Dario Sleep, extending its provider-backed cardiometabolic platform into women's health and sleep categories. The AI-enabled programs combine digital engagement, behavioral coaching and clinical care, and are expected to begin contributing revenue in Q4 2026.
Why it matters — The expansion into two new clinical categories signals further execution of Dario's provider-backed care strategy and broadens its participation in reimbursement-driven healthcare services.
The 4 Wall Street analysts covering DarioHealth Corp. have a median 12-month price target of $12, with estimates ranging from $10 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering DarioHealth Corp., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DarioHealth Corp. 41 out of 100 across roughly 4,600 US stocks as at 11 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 11 Aug 2026, DarioHealth Corp. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +49.6% from the last close, and Ticker Nerd's factor model ranks DarioHealth Corp. 41 out of 100 as at 11 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DarioHealth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $28 over the next 12 months.
DarioHealth Corp. returned -10.2% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
DarioHealth Corp. is an innovative digital health company focused on revolutionizing the way people manage chronic conditions such as diabetes, hypertension, and weight management.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript". DarioHealth Corp. held its Q2 2026 earnings call, and Seeking Alpha published the corresponding transcript of the event. The call covers the company's second-quarter 2026 financial results and commentary.
DarioHealth Corp. is an innovative digital health company focused on revolutionizing the way people manage chronic conditions such as diabetes, hypertension, and weight management. Through its suite of targeted, personalized solutions and real-time data analytics, DarioHealth provides users with the tools to proactively manage their health. The company stands out with its mobile health platform that integrates seamlessly with smartphones, allowing users to monitor and track critical health metrics directly from their devices. This connectivity empowers users and healthcare professionals with immediate access to vital health information. Operating at the intersection of healthcare technology and data science, DarioHealth impacts sectors including telemedicine, digital therapeutics, and patient self-management tools. It serves a global market, addressing the increasing demand for digital health solutions amid the rise of chronic health conditions worldwide. By delivering individualized care experiences and enhancing user engagement, DarioHealth plays a critical role in the evolving landscape of healthcare, offering scalable solutions aimed at improving outcomes and reducing the overall cost of healthcare management.
CEO Mr. Erez Raphael · 160 employees · United States · https://www.dariohealth.com